NUVB Nuvation Bio Inc.
Company Analysis
Latest News
🔴 Nuvation Bio is trading 5% down today amid broader risk-off sentiment
Nuvation Bio is trading at $4.45, down 5.43%, with broader market weakness the likeliest explanation; no company-specific negative catalyst was confirmed. -...
🟢 Nuvation Bio rises 5.5% — Biotech Sector Surges on M&A Activity and Positive Clinical Trial Data
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is experiencing a significant...
🔴 Nuvation Bio is trading 5.5% down amid sector and market weakness
Nuvation Bio is trading at $4.49, down 5.47%, with no fresh company-specific catalyst identified for the October 16 decline. - The move is consistent with...
🔴 Nuvation Bio is trading 5% down
Nuvation Bio is trading 5.06% down at $4.88 on October 5, 2026; no clear company-specific announcement explaining the decline was found. - The company’s...
🔴 Nuvation Bio is trading 5% down
Nuvation Bio is trading at $5.28, down 5.13%, with no clear company-specific announcement explaining the October 2 decline. - The latest item on the company...
🟢 Nuvation Bio is trading 5.5% up in pre-market with no clear new catalyst identified
Nuvation Bio is trading 5.54% higher in pre-market at $5.93, versus the September 29 close of $5.62; no clear new catalyst dated September 30 was...
🔴 Nuvation Bio is trading 4.2% down today amid risk-off markets following Iran proposal rejection
Nuvation Bio is trading 4.2% down at $5.50, with broader macro sentiment the likeliest context rather than a confirmed company-driven move. - No new...
🔴 Nuvation Bio is trading 4.18% down today as broader market weakness pressures risk-sensitive stocks
Nuvation Bio is trading 4.18% down now at $5.84 as broader equity weakness pressures risk-sensitive stocks. - U.S. indices are lower on September 23, 2026,...
Nuvation Bio Rises, FDA Approves Ibtrozi Label Showing 4-Year Cancer Benefit
Nuvation Bio received U.S. Food and Drug Administration (FDA) approval for a supplemental New Drug Application for Ibtrozi (taletrectinib) four months ahead of...
🟢 Nuvation Bio rises 5.1% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🟢 Nuvation Bio is trading 5.5% up in pre-market as yields ease after Fed decision
Nuvation Bio is trading 5.5% up at $6.10 after a broad pre-market recovery, likely reflecting improved global risk appetite following the Federal Reserve’s...
🔴 Nuvation Bio falls 4.5% — Biotech Sector Declines on Key Drug Trial Failure and Shifting Investor Sentiment
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🔴 Nuvation Bio is trading 6.1% down in pre-market amid broader risk-off trading
Nuvation Bio is trading 6.1% down at $5.70, with the decline appearing consistent with broader risk-off trading and no new company-specific catalyst identified...
🔴 Nuvation Bio is trading 4.06% down today with no clear company-specific catalyst
Nuvation Bio is trading 4.06% down now at $6.03, with no clear company-specific catalyst emerging on September 11, 2026. - Conference commentary on IBTROZI,...
🔴 Nuvation Bio is trading 4.1% down today with no clear company-specific catalyst
Nuvation Bio is trading 4.1% down at $6.25 after no clear company-specific catalyst emerged on September 10, 2026. - A September 9 Citigroup summit discussion...
🟢 Nuvation Bio is trading 4.3% up today as biotech ETF XBI gains 2.75%
Nuvation Bio is trading at $6.92, up 4.29%, mainly on sector strength, with biotech ETF XBI up 2.75% during regular trading. - No new company-specific...
🟢 Nuvation Bio is trading 4.13% up today — immediate catalyst unconfirmed
Nuvation Bio is trading at $6.93, up +4.13%, while the immediate catalyst remains unconfirmed. - No new company-specific announcement, filing, earnings...
🔴 Nuvation Bio falls 4.0% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🟢 Nuvation Bio is trading 4.47% up in after-hours trading with no confirmed company-specific catalyst
Nuvation Bio is trading at $7.25, up +4.47% in after-hours trading, with no confirmed company-specific catalyst. • It closed at $6.94 on August 26, 2026. •...
🟢 Nuvation Bio rises 4.4% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...